New drug combo trial aims to shrink Hard-to-Treat tumors
NCT ID NCT05536141
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 27 times
Summary
This early-phase study tests a new drug called casdatifan (AB521) in people with advanced kidney cancer or other solid tumors that haven't responded to standard treatments. The goal is to find safe doses and see how well the drug works alone or combined with other cancer therapies. About 362 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBirmingham, Alabama, 35294, United States
-
Research Site
RECRUITINGSan Diego, California, 92093, United States
-
Research Site
RECRUITINGSanta Monica, California, 90404, United States
-
Research Site
RECRUITINGMiami, Florida, 33136, United States
-
Research Site
RECRUITINGAtlanta, Georgia, 30322-1013, United States
-
Research Site
RECRUITINGLouisville, Kentucky, 40202, United States
-
Research Site
RECRUITINGNew Orleans, Louisiana, 70121, United States
-
Research Site
RECRUITINGBaltimore, Maryland, 21287, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02215, United States
-
Research Site
RECRUITINGDetroit, Michigan, 48201, United States
-
Research Site
RECRUITINGDetroit, Michigan, 48202, United States
-
Research Site
RECRUITINGOmaha, Nebraska, 68124, United States
-
Research Site
RECRUITINGNew York, New York, 10029, United States
-
Research Site
RECRUITINGNew York, New York, 10065, United States
-
Research Site
RECRUITINGCleveland, Ohio, 44106, United States
-
Research Site
RECRUITINGCleveland, Ohio, 44195, United States
-
Research Site
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
Research Site
RECRUITINGNashville, Tennessee, 37203, United States
-
Research Site
RECRUITINGNashville, Tennessee, 37240, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Research Site
NOT_YET_RECRUITINGCamperdown, Australia
-
Research Site
NOT_YET_RECRUITINGMelbourne, Australia
-
Research Site
RECRUITINGSydney, Australia
-
Research Site
RECRUITINGSeoul, South Korea
-
Research Site
NOT_YET_RECRUITINGBarcelona, Spain
Conditions
Explore the condition pages connected to this study.